B[China implements medical rehabilitation and nursing capacity expansion and improvement project] October 8th, recently, with the approval of the State Council, the National Health Commission and the National Development and Reform Commission jointly issued the "Implementation Plan for the Medical Rehabilitation and Nursing Capacity Expansion and Improvement Project". The "Plan" focuses on expanding medical rehabilitation nursing resources and improving medical rehabilitation nursing service capabilities, and proposes 13 tasks and measures in 6 parts. It is an important document to guide the construction and development of the medical rehabilitation nursing service system. It is proposed to focus on "capacity expansion, quality improvement, balance and continuity", insist on doing our best, within our capabilities, adapting measures to local conditions, and implement steadily, focusing on the grassroots level to coordinate and increase the supply of medical rehabilitation nursing resources, further improve service capabilities, and effectively enhance the accessibility of rehabilitation nursing services for urban and rural residents. The work goal is that by 2030, significant results will be achieved in the expansion and upgrading of medical rehabilitation and nursing care, and a service system with complete functions, top-down linkage, integration of traditional Chinese and Western medicine, and efficient and accessible service system will be basically established to better meet the health needs of the entire population, in all aspects, and throughout the life cycle. B[Afternoon Session of the Second Day of the 2026 National Talks: Representatives from Merck, AstraZeneca, Roche, Innovent Biologics, Changchun Kinsey and other companies entered the venue one after another] September 6th, at around 13:00 today, the afternoon session of the 2026 National Basic Medical Insurance Drug List Negotiation Bidding and Commercial Insurance Innovative Drug List Price Negotiation officially opened. Reporters observed at the scene that negotiators from Merck, AstraZeneca, Roche, Sanofi, Innovent Biologics, Suzhou Shengdi, Beijing Northland, Hengrui Pharmaceuticals, Lepu Biotech and other companies entered the venue. There were about 20 negotiating companies. Compared with yesterday and this morning, there were significantly more people from foreign companies. (Reporters Lu Afeng and Yu Miao) B[Morning session on the second day of the 2026 National Talks: Negotiations on some oncology drugs begin Representatives from Chinese and foreign companies such as Heyuan Biotech, Astellas, Hengrui Pharmaceuticals, etc. attended the event] On September 6, reporters learned from the on-site negotiations on the 2026 National Medical Insurance Catalog and the Price Negotiation on the Commercially Insured Innovative Drug Catalog that the second day of the 2026 National Talks was held on August 8 Starting around 12:00 p.m., representatives from nearly 20 domestic and foreign pharmaceutical companies, including Heyuan Biologics, Yuanda Pharmaceuticals, Hengrui Pharmaceuticals, Qilu Pharmaceuticals, Eli Lilly, Chia Tai Tianqing, a subsidiary of China National Biopharmaceuticals, CSPC Pharmaceutical Group, Sanofi, Innovent Biologics, and Novartis, entered the venue one after another to start negotiations. Among them, Heyuan Biotech's CAR-T drug Nachiolense Injection entered the Commercial Insurance Innovative Drug Catalogue last year. This year, it applied to enter the Basic Medical Insurance Catalog and passed the preliminary review. It also applied for adjustment of indications in the Commercial Insurance Catalog. It is expected that the types of drugs negotiated in the morning will include tumor treatment drugs. (Reporters Lu Afeng and Yu Miao) A[Beijing: Accelerate the formation of a global digital economy demonstration center, a source of global medical and health innovation, a gathering place for international modern service industries, and an open highland for two-way mutual promotion] On August 31, the Beijing Municipal Bureau of Commerce issued the "Beijing High-level Open Economic Development Plan during the "15th Five-Year Plan" Period", which proposed that by 2030, the national service industry will expand the opening-up comprehensive demonstration zone and the China (Beijing) Free Trade Pilot Zone (referred to as the "two zones"). ") and the China International Fair for Trade in Services, Zhongguancun Forum, Financial Street Forum, and Beijing Cultural Forum (referred to as the "Four Platforms") have further enhanced their role in promoting opening up, achieved greater breakthroughs in opening up key areas and reforming key links, accelerating the construction of a new higher-level open economic system, and accelerating the formation of a global digital economy demonstration leader, a global source of innovation in medicine and health, a gathering place for international modern service industries, and an open highland for two-way mutual promotion. By 2035, Beijing will be at the forefront of serving the country's new pattern of opening up, its ability to participate in the governance of international economic and trade rules will be greatly improved, and the new advantages of a higher-level open economy will be further enhanced.
— All loaded —
